US20070020384A1 - Environmentally benign crop protection agents - Google Patents

Environmentally benign crop protection agents Download PDF

Info

Publication number
US20070020384A1
US20070020384A1 US11/475,833 US47583306A US2007020384A1 US 20070020384 A1 US20070020384 A1 US 20070020384A1 US 47583306 A US47583306 A US 47583306A US 2007020384 A1 US2007020384 A1 US 2007020384A1
Authority
US
United States
Prior art keywords
phenyl
alkyl
sulfate
aryl
zosteric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/475,833
Inventor
Randall Alberte
Richard Zimmerman
Robert Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/475,833 priority Critical patent/US20070020384A1/en
Publication of US20070020384A1 publication Critical patent/US20070020384A1/en
Assigned to CUTLER, ELIOT, AMORY, DANIEL reassignment CUTLER, ELIOT SECURITY AGREEMENT Assignors: CERNO BIOSCIENCES, LLC
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D5/00Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
    • C09D5/16Antifouling paints; Underwater paints
    • C09D5/1606Antifouling paints; Underwater paints characterised by the anti-fouling agent
    • C09D5/1612Non-macromolecular compounds
    • C09D5/1625Non-macromolecular compounds organic
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L17/00Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
    • A61L17/005Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters containing a biologically active substance, e.g. a medicament or a biocide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001Use of materials characterised by their function or physical properties
    • A61L24/0015Medicaments; Biocides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005Use of materials characterised by their function or physical properties
    • A61L33/0011Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0041Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C305/00Esters of sulfuric acids
    • C07C305/26Halogenosulfates, i.e. monoesters of halogenosulfuric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602Type of release, e.g. controlled, sustained, slow
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S428/00Stock material or miscellaneous articles
    • Y10S428/907Resistant against plant or animal attack
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S47/00Plant husbandry
    • Y10S47/11The application of protective coatings to plants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989Microcapsule with solid core [includes liposome]

Definitions

  • non-biological fungicides are toxic chemicals to the fungi, as well as to the environment when they enter drinking water supplies and natural waters and can be toxic to animals and humans through accidental contact. In addition, because many of the chemicals generate resistance in the target organisms.
  • Biological control is based on inhibition by some microorganisms on the growth and action of pathogenic fungi, which cause rotting (See for example, U.S. Pat. No. 4,975,277 and EP 0 781 843 A1).
  • pathogenic fungi which cause rotting
  • the effectiveness of various strains may be diminished during storage and harvesting.
  • the instant invention features crop protection compounds having the general structure 1: wherein
  • X represents —OH, —O(aryl), —O(acyl), —O(sulfonyl), —CN, F, Cl, or Br;
  • Y represents O, S, Se, or NR
  • Z represents optionally substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or —(CH 2 ) m —R 80 ;
  • R represents independently for each occurrence hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or —(CH 2 ) m —R 80 ;
  • R 80 represents independently for each occurrence aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl;
  • n is an integer in the range 0 to 8 inclusive.
  • Other preferred compounds are salts of the compounds in structure 1.
  • the instant claimed compounds interfere with the attachment of organisms to surfaces, thereby having broad applicability in effectively inhibiting the attachment of a variety of organisms.
  • the compounds are relatively safe for wide-spread environmental use, as they naturally degrade into carbon dioxide and water, or simple organic acids.
  • certain preferred compounds have a relatively short half-life after release, rendering them particularly well-suited for widespread environmental use. Yet other preferred compounds can be readily synthesized.
  • Particularly preferred compounds include: p-iso-butylphenyl chlorosulfate, p-tert-butylphenyl chlorosulfate, p-tert-amylphenyl chlorosulfate, p-tert-cumylphenyl chlorosulfate, 4-pentylphenyl chlorosulfate, 4-(1-methylheptyl)phenyl chlorosulfate, methyl chlorosulfate, octyl chlorosulfate, bisphenyl diacid sulfate, p-iso-butylphenyl sulfate, p-tert-butylphenyl sulfate, p-tert-amylphenyl sulfate, p-tert-cumylphenyl sulfate, 4-pentylphenyl sulfate, 4-(1-methylheptyl)phenyl sul
  • FIG. 1 is a bar graph plotting the average number of anthracnose lesions on the leaf and petioles of detached Chandler strawberries when treated with a range of concentrations of the sodium salt of zosteric acid.
  • Anthracnose disease control efficacy of 73.6% was achieved with a 2% (w/v) solution of zosteric acid in phosphate buffer containing 0/1% TweenTM 20.
  • Colletotrichum fragariae isolate CF63conidia 1.5 ⁇ 10 6 spores/mL were used to induce disease.
  • FIG. 2 is a graph showing the average disease severity and phytotoxicity ratings of Chandler strawberry whole plants when treated with a range of concentrations of the sodium salt of zosteric acid and an analog. Colletotrichum fragariae isolate isolate CF63conidia (1.5 ⁇ 10 6 spores/mL) were used to induce disease.
  • FIG. 3 is a graph showing the result of microscopic studies indication that the sodium salt of zosteric acid and it TPPC analog were the most effective compounds at inhibiting spore attachment ( C. acutatum ) to a glass surface.
  • FIG. 4 is a graph showing the results of microscopic evaluation of C. acutatum spores. As can be seen in the graph. 1% zosteric acid prevented 99% of the spores from germinating during the 24 hour incubation.
  • FIG. 6 is a diagrammatic representation of the results of bacterial attachment assays performed with the marine bacterium Oceanosprillum , cultured in the presence and absence of either zosteric acid or methyl sulfate.
  • FIG. 7 is a diagrammatic representation of the results of bacterial attachment assays performed with the marine bacterium Oceanosprillum , cultured in the presence and absence of either zosteric acid or octyl sulfate.
  • FIG. 8 is a diagrammatic representation of the results of bacterial attachment assays performed with the bacterium Alteromonas atlantica , performed in the presence and absence of either, zosteric acid, octyl sulfate, or methyl sulfate.
  • FIG. 9 is a diagrammatic representation of the results of fungal attachment and growth assays using the fungus Aureobasidium pullulans (a shower fungus that stains grout) grown in the presence and absence of zosteric acid, where fungal abundance represents the attachment of A. pullulans to the exposed surface.
  • FIG. 10 is a diagrammatic representation of the results of agglutination of the bacterium Shewanella putrefaciens induced by the presence of increased amounts of zosteric acid, measured by the percent transmission (% T) of the liquid cultures at wavelength 600 nm. Agglutination is indicated by the concentration-dependent increase in % T of cultures grown in the presence of zosteric acid. In this case, relatively high levels of % T exhibited by the zosteric acid-exposed cultures do not reflect differences in growth, as counts of viable colony forming units exhibited no difference in cell density at eight hours.
  • the instant invention is based, at least in part, on the finding described in detail in the following Example 1, that compounds of the invention inhibit attachment of parasitic fungi spores to plants, as well as hyphal production from previously attached spores. Even after prolonged exposure, the presence of the compounds of the invention on the plants did not result in any toxic or growth inhibitory effect.
  • the compounds of the invention provide a highly effective antifungal agent.
  • the compounds are broad-based antifungal agents.
  • a series of investigations on several species of bacteria, microalgae, macroalgal spores and invertebrates has confirmed that the inhibitory mode-of-action is through a non-toxic means (Zimmerman et al., (1995) U.S. Pat. No. 5,384,176; Zimmerman et al., (1997) U.S. Pat. No. 5,607,741; Todd et al., Phytochemistry 34: 401-404 (1993); Sundberg et al., Naval Research Reviews (1997) 4: 51-59).
  • acylamino is art-recognized and refers to a moiety that can be represented by the general formula: wherein R 9 is as defined above, and R′ 11 represents a hydrogen, an alkyl, an alkenyl or —(CH 2 ) m —R 8 , where m and R 8 are as defined above.
  • alkenyl and alkynyl refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that comprise a double or triple bond, respectively.
  • alkoxyl refers to an alkyl group, as defined above, having an oxygen radical attached thereto.
  • Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like.
  • An “ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as can be represented by one of —O-alkyl, —O-alkenyl, —O-alkynyl, —O—(CH 2 ) m —R 8 , where m and R 8 are described above.
  • alkyl refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups.
  • a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C 1 -C 30 for straight chain, C 3 -C 30 for branched chain), and more preferably 20 or fewer.
  • preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.
  • alkyl (or “lower alkyl”) as used throughout the specification and claims is intended to include both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone.
  • Such substituents can include, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an ester, a formyl, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety.
  • a halogen such as a hydroxyl,
  • the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
  • the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), —CF 3 , —CN and the like.
  • Cycloalkyls can be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, —CF 3 , —CN, and the like.
  • alkylthio refers to an alkyl group, as defined above, having a sulfur radical attached thereto.
  • the “alkylthio” moiety is represented by one of —S-alkyl, —S-alkenyl, —S-alkynyl, and —S—(CH 2 ) m —R 8 , wherein m and R 8 are defined above.
  • Representative alkylthio groups include methylthio, ethylthio, and the like.
  • amido is art recognized as an amino-substituted carbonyl and includes a moiety that can be represented by the general formula: wherein R 9 , R 10 are as defined above. Preferred embodiments of the amide will not include imides which may be unstable.
  • amine and “amino” are art recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that can be represented by the general formula: wherein R 9 , R 10 and R′ 10 each independently represent a hydrogen, an alkyl, an alkenyl, —(CH 2 ) m —R 8 , or R 9 and R 10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R 8 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8.
  • R 9 or R 10 can be a carbonyl, e.g., R 9 , R 10 and the nitrogen together do not form an imide.
  • R 9 and R 10 each independently represent a hydrogen, an alkyl, an alkenyl, or —(CH 2 ) m —R 8 .
  • alkylamine as used herein means an amine group, as defined above, having a substituted or unsubstituted alkyl attached thereto, i.e., at least one of R 9 and R 10 is an alkyl group.
  • an “aprotic solvent” means a non-nucleophilic solvent having a boiling point range above ambient temperature, preferably from about 25° C. to about 190° C., more preferably from about 80° C. to about 160° C., most preferably from about 80° C. to 150° C., at atmospheric pressure.
  • solvents are acetonitrile, toluene, DMF, diglyme, THF or DMSO.
  • aryl as used herein includes 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
  • aryl heterocycles or “heteroaromatics”.
  • the aromatic ring can be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, —CF 3 , —CN, or the like.
  • substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate,
  • aryl also includes polycyclic ring systems having two or more rings in which two or more carbons are common to two adjoining rings (the rings are “fused”) wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
  • carrier refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.
  • carbonyl is art recognized and includes such moieties as can be represented by the general formula: wherein X is a bond or represents an oxygen or a sulfur, and R 11 represents a hydrogen, an alkyl, an alkenyl, —(CH 2 ) m —R 8 or a pharmaceutically acceptable salt, R′ 11 represents a hydrogen, an alkyl, an alkenyl or —(CH 2 ) m —R 8 , where m and R 8 are as defined above. Where X is an oxygen and R 11 or R′ 11 is not hydrogen, the formula represents an “ester”.
  • a “coating” refers to any temporary, semipermanent or permanent layer or covering.
  • a coating can be a gas, vapor, liquid, paste, semi-solid or solid.
  • a coating can be applied as a liquid and solidify into a hard coating. Examples of coatings include sprays, liquids, gases, vapors, gels, powders, waters, wetters, detergents, oils.
  • Contacting refers to any means for providing the compounds of the invention to a plant of plant component. Contacting can include spraying, wetting, immersing, dipping, painting, bonding, adhering or otherwise providing a surface with a compound of the invention.
  • phrases “effective amount” refers to an amount of the disclosed antifouling compounds that reduces the number of organisms that attach to a defined surface (cells/mm 2 ) of a plant or plant component relative to the number that attach to an untreated surface. Particularly preferred are amounts that reduce the number of organisms that attach to the surface by a factor of at least 2. Even more preferred are amounts that reduce the surface attachment of organisms by a factor of 4, more preferably by a factor of 6, 8, 10 or more. Especially preferred is that amount, which will completely inhibit fungal growth (i.e. inhibit the spread of fungal mycelia) without causing necrotic tissue to the plant.
  • electron-withdrawing group is recognized in the art, and denotes the tendency of a substituent to attract valence electrons from neighboring atoms, i.e., the substituent is electronegative with respect to neighboring atoms.
  • a quantification of the level of electron-withdrawing capability is given by the Hammett sigma (a) constant. This well known constant is described in many references, for instance, J. March, Advanced Organic Chemistry , McGraw Hill Book Company, New York, (1977 edition) pp. 251-259.
  • Exemplary electron-withdrawing groups include nitro, ketone, aldehyde, sulfonyl, trifluoromethyl, —CN, chloride, and the like.
  • Exemplary electron-donating groups include amino, methoxy, and the like.
  • half-life refers to the amount of time required for half of a compound to be eliminated or degraded by natural processes.
  • Preferred compounds have a half-life of less than one year. Particularly preferred are half-lives in the range of 1 to 60 days in the environment.
  • heteroatom as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorous.
  • heterocyclyl or “heterocyclic group” refer to 3- to 10-membered ring structures, more preferably 3- to 7-membered rings, whose ring structures include one to four heteroatoms. Heterocycles can also be polycycles.
  • Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, perimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, ox
  • the heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF 3 , —CN, or the like.
  • substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxy
  • lower alkyl as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure. Likewise, “lower alkenyl” and “lower alkynyl” have similar chain lengths. Preferred alkyl groups are lower alkyls. In preferred embodiments, a substituent designated herein as alkyl is a lower alkyl.
  • nitro means —NO 2 ;
  • halogen designates —F, —Cl, —Br or —I;
  • sulfhydryl means —SH;
  • hydroxyl means —OH; and
  • sulfonyl means —SO 2 —.
  • ortho, meta and para apply to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively.
  • 1,2-dimethylbenzene and ortho-dimethylbenzene are synonymous.
  • a “phosphoryl” can in general be represented by the formula: wherein Q 1 represented S or O, and R 46 represents hydrogen, a lower alkyl or an aryl.
  • the phosphoryl group of the phosphorylalkyl can be represented by the general formula: wherein Q 1 represented S or O, and each R 46 independently represents hydrogen, a lower alkyl or an aryl, Q 2 represents O, S or N.
  • Q 1 is an S
  • the phosphoryl moiety is a “phosphorothioate”.
  • Plant refers to any member of the plant kingdom, at any stage of its life cycle, including seeds, germinated seeds, seedlings, or mature plants.
  • Plant cell refers to a cell from a plant or plant component.
  • Plant component refers to a portion or part of a plant. Examples include: seeds, roots, stems, vascular systems, fruits (further including pip fruits (e.g. apples, pears, quinces)), citrus fruits (oranges, lemons, limes, grapefruits, mandarins, nectarines), stone fruits (peaches apricots, plums, cherrries, avocados, grapes), berries (strawberries, blueberries, raspberries, blackberries)), leaves, grains and vegetables.
  • fruits further including pip fruits (e.g. apples, pears, quinces)
  • citrus fruits ranges, lemons, limes, grapefruits, mandarins, nectarines
  • stone fruits peaches apricots, plums, cherrries, avocados, grapes), berries (strawberries, blueberries, raspberries, blackberries)
  • leaves grains and vegetables.
  • a “plant pathogen” refers to an organism (bacteria, virus, protist, algae or fungi) that infects plants of plant components. Examples include molds, fungi and rot that typical use spores to infect plants or plant components (e.g fruits, vegetables, grains, stems, roots). Spores must recognize the host, attach, germinate, penetrate host tissues, and proliferate hyphae that will allow the fungus access to nutrients for growth and reproduction. Examples include: Botrytis sp. ( B. cinerea ), Penicillium sp. ( P. expansum, P. italicum, P. digitalum ), Rhizopus sp. ( R. sulonifer, R.
  • Verticillium spp. V. alboatrum, V. dahliae ), Unicula spp. ( U. necator ), Plasmopara spp. ( P. viticola ), Guignardia spp. ( G. bidwellii ), Cercospora spp. ( C. arachidicola ), Scelrotinia spp. ( S. scerotiorum ), Puccinia spp. ( P. arachidis ), Aspergillus spp. ( A. flavus ), Venturia spp ( V. inaequalis ) Podosphaera spp. ( P. leucotricha ), Pythiun spp., Sphaerotheca ( S. macularis ) and Bacillus spp. ( B. subitlis ).
  • a “polar, aprotic solvent” means a polar solvent as defined above which has no available hydrogens to exchange with the compounds of this invention during reaction, for example DMF, acetonitrile, diglyme, DMSO, or THF.
  • a “polar solvent” means a solvent which has a dielectric constant (e) of 2.9 or greater, such as DMF, THF, ethylene glycol dimethyl ether (DME), DMSO, acetone, acetonitrile, methanol, ethanol, isopropanol, n-propanol, t-butanol or 2-methoxyethyl ether.
  • Preferred solvents are DMF, DME, NMP, and acetonitrile.
  • polycyclyl or “polycyclic group” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”. Rings that are joined through non-adjacent atoms are termed “bridged” rings.
  • Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF 3 , —CN, or the like.
  • substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, si
  • protecting group means temporary modifications of a potentially reactive functional group which protect it from undesired chemical transformations.
  • protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively.
  • the field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2 nd ed.; Wiley: New York, 1991).
  • Release rate refers to the rate of delivery or diffusion of a compound to and ultimately from a surface.
  • the release rate may be constant or sustained over a period of time or may be variable. However, constant, controlled or sustained release rates are generally preferred. Steady state or sustained release may be effected by use of a reservoir membrane (i.e. a two layer coating in which one layer contains the active agent and the other creates a membrane through which the active agent can be released).
  • the active agent could alternatively be microencapsulated within any of a variety of matrices for sustained release.
  • Preferred release rates are in the range of about 100 to about 200 ⁇ gcm ⁇ 2 d ⁇ 1 is useful for temporary uses of uses that require reapplication. For more sustained applications, preferred release rates are in the range of about 1 to about 100 ⁇ gcm ⁇ 2 d ⁇ 1 , more preferably in the range of about 1-50 and still more preferably in the range of about 1-25 or better yet, 1-15.
  • soluble refers to the ability to be loosened or dissolved.
  • a “solubilized” compound has been loosened or dissolved (e.g. into a fluid).
  • the term “substituted” is contemplated to include all permissible substituents of organic compounds.
  • the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds.
  • Illustrative substituents include, for example, those described hereinabove.
  • the permissible substituents can be one or more and the same or different for appropriate organic compounds.
  • the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
  • substitution or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
  • a “sulfate binding moiety” refers to a moiety that is capable of binding or otherwise associating with a sulfate or sulfonate group.
  • sulfonate is art recognized and includes a moiety that can be represented by the general formula: in which R 41 is an electron pair, hydrogen, alkyl, cycloalkyl, or aryl.
  • sulfoxido or “sulfinyl”, as used herein, refers to a moiety that can be represented by the general formula: in which R 44 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aralkyl, or aryl.
  • Analogous substitutions can be made to alkenyl and alkynyl groups to produce, for example, aminoalkenyls, aminoalkynyls, amidoalkenyls, amidoalkynyls, iminoalkenyls, iminoalkynyls, thioalkenyls, thioalkynyls, carbonyl-substituted alkenyls or alkynyls.
  • surface refers to any interface between an object and a fluid environment, which permits at least intermittent contact between the object and the fluid environment. Fluids contacting the surfaces can be stagnant or flowing, and can flow intermittently or continuously, with laminar or turbulent or mixed rheologies. A surface upon which a biofilm can form can be dry at times with sporadic fluid contact, or can have any degree of fluid exposure including total immersion. Fluid contact with the surface can take place via aerosols or other means for air-borne fluid transmission.
  • sustained release or “controlled release refers to a relatively constant or prolonged release of a compound of the invention from a surface. This can be accomplished through the use of diffusional systems, including reservoir devices in which a core of a compound of the invention is surrounded by a porous membrane or layer, and also matrix devices in which the compound is distributed throughout an inert matrix. Microencapsulation techniques can also be used to maintain a sustained focal release of a compound of the invention. Microencapsulation may also be used for providing improved stability.
  • the encapsulated product can take the form of for example, spheres, aggregates of core material embedded in a continuum of wall material, or capillary designs.
  • the core material of a microcapsule containing a compound of the invention may be in the form of a liquid droplet, an emulsion, a suspension of solids, a solid particle, or a crystal.
  • the skilled artisan will be aware of numerous materials suitable for use as microcapsule coating materials, including, but not limited to, organic polymers, hydrocolloids, lipids, fats, carbohydrates, waxes, metals, and inorganic oxides. Silicone polymers are the most preferred microcapsule coating material for treatment of surfaces. Microencapsulation techniques are well known in the art and are described in the Encyclopedia of Polymer Science and Engineering, Vol. 9, pp. 724 et seq. (1989) hereby incorporated by reference.
  • Me, Et, Ph, Tf, Nf, Ts, Ms, and dba represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, nonafluorobutanesulfonyl, p-toluenesulfonyl, methanesulfonyl, and dibenzylideneacetone, respectively.
  • a more comprehensive list of the abbreviations utilized by organic chemists of ordinary skill in the art appears in the first issue of each volume of the Journal of Organic Chemistry ; this list is typically presented in a table entitled Standard List of Abbreviations . The abbreviations contained in said list, and all abbreviations utilized by organic chemists of ordinary skill in the art are hereby incorporated by reference.
  • hydrocarbon is contemplated to include all permissible compounds having at least one hydrogen and one carbon atom.
  • permissible hydrocarbons include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic organic compounds which can be substituted or unsubstituted.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1: wherein
  • X represents —OH, —O(aryl), —O(acyl), —O(sulfonyl), —CN, F, Cl, or Br;
  • Y represents O, S, Se, or NR
  • Z represents optionally substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or —(CH 2 ) m —R 80 ;
  • R represents independently for each occurrence hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or —(CH 2 ) m —R 80 ;
  • R 80 represents independently for each occurrence aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl;
  • n is an integer in the range 0 to 8 inclusive.
  • Particularly stable compounds are represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Y represents O.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Z represents optionally substituted alkyl, aryl, or —(CH 2 ) m —R 80 .
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein R represents H or alkyl.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; and Y represents O.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; and Y represents O.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; and Z represents optionally substituted alkyl, aryl, or —(CH 2 ) m —R 80 .
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; and Z represents optionally substituted alkyl, aryl, or —(CH 2 ) m —R 80 .
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; and Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; and Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; and Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • X represents —OH, F, Cl, or Br
  • Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phen
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; and Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(11,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • X represents —OH or Cl
  • Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(11,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Y represents O; and Z represents optionally substituted alkyl, aryl, or —(CH 2 ) m —R 80 .
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Y represents O; and Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Y represents O; and Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(11,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • Y represents O
  • Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(11,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; Y represents O; and Z represents optionally substituted alkyl, aryl, or —(CH 2 ) m —R 80 .
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; Y represents O; and Z represents optionally substituted alkyl, aryl, or —(CH 2 ) m —R 80 .
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; Y represents O; and Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; Y represents O; and Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; Y represents O; and Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1,1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • X represents —OH, F, Cl, or Br
  • Y represents O
  • Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1,1-methyl-1-phenylethyl)phenyl
  • compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; Y represents O; and Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1,1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • general structure 1 wherein X represents —OH or Cl; Y represents O; and Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1,1-methyl-1-phenylethyl)phenyl, or 4-(1-
  • composition of the invention can be varied as required to optimize the overall chemical properties of the particular compound for specific uses, while retaining the activity.
  • the length of an alkyl chain can be extended or shortened to control the rate of dissolution of the compound from a structure or a coating.
  • additional functional groups can be added to the alkyl chain to further vary the chemical nature of the molecule.
  • Octyl sulfate is an alkyl sulfate surfactant with extensive industrial applications, and is manufactured by several large chemical companies. To investigate potential AF properties of the sulfate ester octyl sulfate, it was incorporated into an inert coating material that was then coated onto a surface to be exposed to conditions that support the formation of marine algal biofilms.
  • Each test consisted of a control set (with no sulfate esters) and sample sets containing the test molecules.
  • the first test group consisted of a control sample set, a zosteric acid (5 mM) sample set, and an octyl sulfate (5 mM) sample set.
  • the second test group consisted of a control sample set, a zosteric acid (5 mM) sample set, and a methyl sulfate (5 mM) sample set.
  • Sample sets consisted of five 50 mL sterile centrifuge tubes, with each tube containing a glass microscope slide, 50 ml of artificial seawater (ASTM—American Society for testing and materials) with the dissolved sulfate ester, inoculated with an Oceanosprillum culture at 1 ⁇ 10 6 cells/mL. Sample sets were incubated at 23 C, with shaking so that the surface of the slides were horizontal. Over a 6-hour period, individual tubes were taken from the sample sets and tested for microbial adhesion.
  • Alteromonas atlantica adhesion tests consisted of a control sample set, a zosteric acid (5 mM) sample set, an octyl sulfate (5 mM) sample set, and a methyl sulfate (5 mM) set.
  • a sample set consisted of six 60 mL sterile centrifuge tubes. Each tube contained a glass microscope slide and 50 mL of modified ASTM seawater (American Society for Testing and Materials (1986) D1141-86, ASTM, Philadelphia, Pa.) with dissolved agent, inoculated with Alteromonas atlantica culture to an initial cell density of 1 ⁇ 10 6 cells/mL.
  • the modified seawater consisted of normal ASTM seawater ingredients, however-the carbon source glycerol, was only 1000th the normal strength, 0.1 L/L instead of 100 L/L, and was void of an amino acid source (casamino acids), in order to allow enough carbon for attachment, but not for significant cell growth.
  • the presence of octyl sulfate or methyl sulfate in the medium significantly reduced bacterial adhesion to the glass slides when compared to controls in which no sulfate ester molecule was present.
  • Methyl sulfate inhibited Oceanosprillum adhesion to an extent similar to the proven AF agent zosteric acid, with each compound promoting roughly a two fold reduction in bacterial attachment, relative to control.
  • octyl sulfate inhibited Oceanosprillum adhesion to an even greater extent than zosteric acid.
  • Aureobasidium pullulans (ATCC 34261) was grown on potato-dextrose agar and harvested according to ASTM G-2 1-90 protocols (American Society for Testing and Materials (1986) D1141-86, ASTM, Philadelphia, Pa.). The resulting spore suspension was used to inoculate liquid culture tubes containing 35 mL of growth medium (nutrient salts with 5 mM sucrose) and 15 mM zosteric acid. Zosteric acid-free medium was prepared as a control. A sterile microscope slide was added to each tube, the tubes were sealed and placed on a rotary shaker table at room temperature. One tube was harvested each day by removing the slide and counting the number of attached spores by direct microscopic counts, as described above.
  • the marine bacterium Shewanella putrefaciens were grown in cultures containing zosteric acid and were subsequently examined for bound zosteric acid using immuno-gold staining with the antibody described above. Electron microscopic examination of immunoprobed S. putrefaciens detected zosteric acid molecules bound to the surface of the bacteria. Furthermore, zosteric acid was observed to be present at high incidence at the sites of cell adhesion. In contrast to these agglutination sites, the majority of the cell surfaces as well as the continuous boundaries between daughter cells in dividing chains, showed no evidence of bound zosteric acid, as indicated by a lack of immuno-gold staining. These results indicate that sulfate esters bind to the surfaces of bacterial cells and suggest a possible relationship between sulfate ester binding sites and the sites of bacterial agglutination.
  • the marine bacterium Shewanella putrefaciens was grown in marine broth in the presence of 16 mM zosteric acid. Dense log phase cells were harvest after 5 hours growth, and preserved in 0.5 ⁇ Kamofsky's fixative (2% formaldehyde, 2.5% gluturaldehyde, 0.05 M sodium cacodylate, 0.25 M sucrose, pH 7.4) for 2 hours, and then transferred to a cacodylate buffer (0.05 M sodium cacodylate, pH 7.4) for storage. Cells were prepared for electron microscopic examination using immuno-gold staining techniques (Harlow, E. and Laine, D., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 359-421; Roth et al., J. Histochem. Cytochem. 26: 1074-1081 (1978)). The primary antibody used in this study was an anti-zosteric acid polyclonal antibody (BAbCo, Richmond, Calif.).
  • zosteric acid concentrations up to 16 mM did not inhibit the growth of S. putrefaciens in liquid culture, the presence of zosteric acid caused significant agglutination of S. putrefaciens in a concentration dependent manner.
  • the agglutination observed was visible to the naked eye, and was more quantitatively detected as a decrease in optical density absorbance in cultures containing zosteric acid ( FIG. 10 ).
  • Counts of viable colony forming units at eight hours revealed no difference in cell density among the different cultures, thus the observed differences in absorption resulted from differences in bacterial agglutination, not differences in growth (cell division) rates among the cultures.
  • zosteric acid promoted cell agglutination, but did not

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Transplantation (AREA)
  • Environmental Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)

Abstract

Disclosed are environmentally benign crop protection compounds that interfere with the attachment of a broad range of plant pathogens to plant cells surfaces.

Description

    BACKGROUND OF THE INVENTION
  • There are more than 50,000 species of fungi. Fewer than 100 are pathogenic to humans. However, more than 10,000 fungi cause disease in plants. Fungal pathogens are extremely costly pests, affecting a broad range of crop plants. It is estimated that anywhere between 20-30% of crop production is lost to fungal pathogens alone worldwide with the greatest losses outside the United States (FAO Report). Losses from fungal pathogens are realized in every stage of crop production ranging from those fungi that attack seeds or germinating seed to those that attack the stems of seedlings, the roots, stems, vascular system, fruits and leaves of mature crops.
  • There are presently a number of widely used fungicide products on the market, including triazoles, anilides, dithiocarbamates, and benzimoidazoles. Total worldwide sales of fungicides in 1995 approached $60 billion with greater than 80% of the market being non-U.S.
  • Essentially all of the non-biological fungicides are toxic chemicals to the fungi, as well as to the environment when they enter drinking water supplies and natural waters and can be toxic to animals and humans through accidental contact. In addition, because many of the chemicals generate resistance in the target organisms.
  • Biological control is based on inhibition by some microorganisms on the growth and action of pathogenic fungi, which cause rotting (See for example, U.S. Pat. No. 4,975,277 and EP 0 781 843 A1). However, there can be great variations in the antifungic activity of different isolates or strains of the same species. In addition, the effectiveness of various strains may be diminished during storage and harvesting.
  • SUMMARY OF THE INVENTION
  • In one aspect, the instant invention features crop protection compounds having the general structure 1:
    Figure US20070020384A1-20070125-C00001

    wherein
  • X represents —OH, —O(aryl), —O(acyl), —O(sulfonyl), —CN, F, Cl, or Br;
  • Y represents O, S, Se, or NR;
  • Z represents optionally substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or —(CH2)m—R80;
  • R represents independently for each occurrence hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or —(CH2)m—R80;
  • R80 represents independently for each occurrence aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl; and
  • m is an integer in the range 0 to 8 inclusive. Other preferred compounds are salts of the compounds in structure 1.
  • The instant claimed compounds interfere with the attachment of organisms to surfaces, thereby having broad applicability in effectively inhibiting the attachment of a variety of organisms. In addition, the compounds are relatively safe for wide-spread environmental use, as they naturally degrade into carbon dioxide and water, or simple organic acids.
  • In addition, certain preferred compounds have a relatively short half-life after release, rendering them particularly well-suited for widespread environmental use. Yet other preferred compounds can be readily synthesized.
  • Particularly preferred compounds include: p-iso-butylphenyl chlorosulfate, p-tert-butylphenyl chlorosulfate, p-tert-amylphenyl chlorosulfate, p-tert-cumylphenyl chlorosulfate, 4-pentylphenyl chlorosulfate, 4-(1-methylheptyl)phenyl chlorosulfate, methyl chlorosulfate, octyl chlorosulfate, bisphenyl diacid sulfate, p-iso-butylphenyl sulfate, p-tert-butylphenyl sulfate, p-tert-amylphenyl sulfate, p-tert-cumylphenyl sulfate, 4-pentylphenyl sulfate, 4-(1-methylheptyl)phenyl sulfate, methyl sulfate, and octyl sulfate, p-sulfoxy cinnamic acid, p-sulfoxy ferulic acid, m,p-disulfoxy caffeic acid, benzoic acid sulfate, vanillic acid sulfate, gentissic acid sulfate, gallic acid sulfate, protochateuic acid and zosteric acid and salts thereof.
  • Other features and advantages of the invention will be apparent from the following detailed description and claims.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a bar graph plotting the average number of anthracnose lesions on the leaf and petioles of detached Chandler strawberries when treated with a range of concentrations of the sodium salt of zosteric acid. Anthracnose disease control efficacy of 73.6% was achieved with a 2% (w/v) solution of zosteric acid in phosphate buffer containing 0/1% Tween 20. Colletotrichum fragariae isolate CF63conidia (1.5×106 spores/mL) were used to induce disease.
  • FIG. 2 is a graph showing the average disease severity and phytotoxicity ratings of Chandler strawberry whole plants when treated with a range of concentrations of the sodium salt of zosteric acid and an analog. Colletotrichum fragariae isolate isolate CF63conidia (1.5×106 spores/mL) were used to induce disease.
  • FIG. 3 is a graph showing the result of microscopic studies indication that the sodium salt of zosteric acid and it TPPC analog were the most effective compounds at inhibiting spore attachment (C. acutatum) to a glass surface.
  • FIG. 4 is a graph showing the results of microscopic evaluation of C. acutatum spores. As can be seen in the graph. 1% zosteric acid prevented 99% of the spores from germinating during the 24 hour incubation.
  • FIG. 5 is a diagrammatic representation of the results of marine algae attachment assays measuring the abundance of algal biofilm development on the inert coating RTV-11 compared to biofilm development on RTV-11 with octyl sulfate incorporated into the coating. Relative algal abundance represents the attachment of the marine algae to the tested surface. Error bars indicate 1 standard error of the mean (n=3) for each treatment. The ratio of the optical densities measured at wavelengths 680 nm and 750 nm (A680/A750) at time O was used as a baseline reference for all samples.
  • FIG. 6 is a diagrammatic representation of the results of bacterial attachment assays performed with the marine bacterium Oceanosprillum, cultured in the presence and absence of either zosteric acid or methyl sulfate.
  • FIG. 7 is a diagrammatic representation of the results of bacterial attachment assays performed with the marine bacterium Oceanosprillum, cultured in the presence and absence of either zosteric acid or octyl sulfate.
  • FIG. 8 is a diagrammatic representation of the results of bacterial attachment assays performed with the bacterium Alteromonas atlantica, performed in the presence and absence of either, zosteric acid, octyl sulfate, or methyl sulfate.
  • FIG. 9 is a diagrammatic representation of the results of fungal attachment and growth assays using the fungus Aureobasidium pullulans (a shower fungus that stains grout) grown in the presence and absence of zosteric acid, where fungal abundance represents the attachment of A. pullulans to the exposed surface.
  • FIG. 10 is a diagrammatic representation of the results of agglutination of the bacterium Shewanella putrefaciens induced by the presence of increased amounts of zosteric acid, measured by the percent transmission (% T) of the liquid cultures at wavelength 600 nm. Agglutination is indicated by the concentration-dependent increase in % T of cultures grown in the presence of zosteric acid. In this case, relatively high levels of % T exhibited by the zosteric acid-exposed cultures do not reflect differences in growth, as counts of viable colony forming units exhibited no difference in cell density at eight hours.
  • DETAILED DESCRIPTION OF THE INVENTION
  • General
  • The instant invention is based, at least in part, on the finding described in detail in the following Example 1, that compounds of the invention inhibit attachment of parasitic fungi spores to plants, as well as hyphal production from previously attached spores. Even after prolonged exposure, the presence of the compounds of the invention on the plants did not result in any toxic or growth inhibitory effect.
  • In addition, greenhouse studies revealed that the compound effectively controlled the disease on plants exposure to abnormal high spore pressures. Again, no detectable phytotoxicity was observed. In evaluations assessing fungal spore attachment on man-made surfaces, it was determined that a compound of the invention provided nearly 100% inhibition of attachment of two species of fungal pathogens. If fungal spores were allowed to attach, the compound provided 100% inhibition of spore germination.
  • By blocking spore attachment, an initial step in the infection process, the compounds of the invention provide a highly effective antifungal agent. In addition, since essentially all fungal plant pathogens use spores to recognize the host plant, attach, germinate, penetrate the host plant tissue and proliferate hyphae that allows the fungus access to the plant's nutrients for growth and reproduction, the compounds are broad-based antifungal agents. In addition a series of investigations on several species of bacteria, microalgae, macroalgal spores and invertebrates has confirmed that the inhibitory mode-of-action is through a non-toxic means (Zimmerman et al., (1995) U.S. Pat. No. 5,384,176; Zimmerman et al., (1997) U.S. Pat. No. 5,607,741; Todd et al., Phytochemistry 34: 401-404 (1993); Sundberg et al., Naval Research Reviews (1997) 4: 51-59).
  • Although the exact mechanism of action is not known, studies indicate that the mechanism involves binding of the compounds to a sulfate binding moiety on cells. The compound or a functional fragment thereof, must then be released for the inhibitory effect. If permanently tethered to a surface, the compounds and sulfate groups tend to promote rather than inhibit the attachment and growth of organisms on a surface.
  • Definitions
  • For convenience, certain terms employed in the specification, examples, and appended claims are described below.
  • The term “acylamino” is art-recognized and refers to a moiety that can be represented by the general formula:
    Figure US20070020384A1-20070125-C00002

    wherein R9 is as defined above, and R′11 represents a hydrogen, an alkyl, an alkenyl or —(CH2)m—R8, where m and R8 are as defined above.
  • The terms “alkenyl” and “alkynyl” refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that comprise a double or triple bond, respectively.
  • The terms “alkoxyl” or “alkoxy” as used herein refers to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. An “ether” is two hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as can be represented by one of —O-alkyl, —O-alkenyl, —O-alkynyl, —O—(CH2)m—R8, where m and R8 are described above.
  • The term “alkyl” refers to the radical of saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In preferred embodiments, a straight chain or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C30 for straight chain, C3-C30 for branched chain), and more preferably 20 or fewer. Likewise, preferred cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5, 6 or 7 carbons in the ring structure.
  • Moreover, the term “alkyl” (or “lower alkyl”) as used throughout the specification and claims is intended to include both “unsubstituted alkyls” and “substituted alkyls”, the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents can include, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an ester, a formyl, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate. For instance, the substituents of a substituted alkyl may include substituted and unsubstituted forms of amino, azido, imino, amido, phosphoryl (including phosphonate and phosphinate), sulfonyl (including sulfate, sulfonamido, sulfamoyl and sulfonate), and silyl groups, as well as ethers, alkylthios, carbonyls (including ketones, aldehydes, carboxylates, and esters), —CF3, —CN and the like. Exemplary substituted alkyls are described below. Cycloalkyls can be further substituted with alkyls, alkenyls, alkoxys, alkylthios, aminoalkyls, carbonyl-substituted alkyls, —CF3, —CN, and the like.
  • The term “alkylthio” refers to an alkyl group, as defined above, having a sulfur radical attached thereto. In preferred embodiments, the “alkylthio” moiety is represented by one of —S-alkyl, —S-alkenyl, —S-alkynyl, and —S—(CH2)m—R8, wherein m and R8 are defined above. Representative alkylthio groups include methylthio, ethylthio, and the like.
  • The term “amido” is art recognized as an amino-substituted carbonyl and includes a moiety that can be represented by the general formula:
    Figure US20070020384A1-20070125-C00003

    wherein R9, R10 are as defined above. Preferred embodiments of the amide will not include imides which may be unstable.
  • The terms “amine” and “amino” are art recognized and refer to both unsubstituted and substituted amines, e.g., a moiety that can be represented by the general formula:
    Figure US20070020384A1-20070125-C00004

    wherein R9, R10 and R′10 each independently represent a hydrogen, an alkyl, an alkenyl, —(CH2)m—R8, or R9 and R10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R8 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8. In preferred embodiments, only one of R9 or R10 can be a carbonyl, e.g., R9, R10 and the nitrogen together do not form an imide. In even more preferred embodiments, R9 and R10 (and optionally R′10) each independently represent a hydrogen, an alkyl, an alkenyl, or —(CH2)m—R8. Thus, the term “alkylamine” as used herein means an amine group, as defined above, having a substituted or unsubstituted alkyl attached thereto, i.e., at least one of R9 and R10 is an alkyl group.
  • An “aprotic solvent” means a non-nucleophilic solvent having a boiling point range above ambient temperature, preferably from about 25° C. to about 190° C., more preferably from about 80° C. to about 160° C., most preferably from about 80° C. to 150° C., at atmospheric pressure. Examples of such solvents are acetonitrile, toluene, DMF, diglyme, THF or DMSO.
  • The term “aryl” as used herein includes 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Those aryl groups having heteroatoms in the ring structure may also be referred to as “aryl heterocycles” or “heteroaromatics”. The aromatic ring can be substituted at one or more ring positions with such substituents as described above, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, —CF3, —CN, or the like. The term “aryl” also includes polycyclic ring systems having two or more rings in which two or more carbons are common to two adjoining rings (the rings are “fused”) wherein at least one of the rings is aromatic, e.g., the other rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
  • The term “carbocycle”, as used herein, refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon.
  • The term “carbonyl” is art recognized and includes such moieties as can be represented by the general formula:
    Figure US20070020384A1-20070125-C00005

    wherein X is a bond or represents an oxygen or a sulfur, and R11 represents a hydrogen, an alkyl, an alkenyl, —(CH2)m—R8 or a pharmaceutically acceptable salt, R′11 represents a hydrogen, an alkyl, an alkenyl or —(CH2)m—R8, where m and R8 are as defined above. Where X is an oxygen and R11 or R′11 is not hydrogen, the formula represents an “ester”. Where X is an oxygen, and R11 is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R11 is a hydrogen, the formula represents a “carboxylic acid”. Where X is an oxygen, and R′11 is hydrogen, the formula represents a “formate”. In general, where the oxygen atom of the above formula is replaced by sulfur, the formula represents a “thiolcarbonyl” group. Where X is a sulfur and R11, or R′11 is not hydrogen, the formula represents a “thiolester.” Where X is a sulfur and R11′ is hydrogen, the formula represents a “thiolcarboxylic acid.” Where X is a sulfur and R11 is hydrogen, the formula represents a “thiolformate.” On the other hand, where X is a bond, and R11 is not hydrogen, the above formula represents a “ketone” group. Where X is a bond, and R11 is hydrogen, the above formula represents an “aldehyde” group.
  • A “coating” refers to any temporary, semipermanent or permanent layer or covering. A coating can be a gas, vapor, liquid, paste, semi-solid or solid. In addition a coating can be applied as a liquid and solidify into a hard coating. Examples of coatings include sprays, liquids, gases, vapors, gels, powders, waters, wetters, detergents, oils.
  • “Contacting” as used herein refers to any means for providing the compounds of the invention to a plant of plant component. Contacting can include spraying, wetting, immersing, dipping, painting, bonding, adhering or otherwise providing a surface with a compound of the invention.
  • The phrase “effective amount” refers to an amount of the disclosed antifouling compounds that reduces the number of organisms that attach to a defined surface (cells/mm2) of a plant or plant component relative to the number that attach to an untreated surface. Particularly preferred are amounts that reduce the number of organisms that attach to the surface by a factor of at least 2. Even more preferred are amounts that reduce the surface attachment of organisms by a factor of 4, more preferably by a factor of 6, 8, 10 or more. Especially preferred is that amount, which will completely inhibit fungal growth (i.e. inhibit the spread of fungal mycelia) without causing necrotic tissue to the plant.
  • The phrase “electron-withdrawing group” is recognized in the art, and denotes the tendency of a substituent to attract valence electrons from neighboring atoms, i.e., the substituent is electronegative with respect to neighboring atoms. A quantification of the level of electron-withdrawing capability is given by the Hammett sigma (a) constant. This well known constant is described in many references, for instance, J. March, Advanced Organic Chemistry, McGraw Hill Book Company, New York, (1977 edition) pp. 251-259. The Hammett constant values are generally negative for electron donating groups (σ[P]=−0.66 for NH2) and positive for electron withdrawing groups (σ[P]=0.78 for a nitro group), σ[P] indicating para substitution. Exemplary electron-withdrawing groups include nitro, ketone, aldehyde, sulfonyl, trifluoromethyl, —CN, chloride, and the like. Exemplary electron-donating groups include amino, methoxy, and the like.
  • The term “half-life” refers to the amount of time required for half of a compound to be eliminated or degraded by natural processes. Preferred compounds have a half-life of less than one year. Particularly preferred are half-lives in the range of 1 to 60 days in the environment.
  • The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, sulfur and phosphorous.
  • The terms “heterocyclyl” or “heterocyclic group” refer to 3- to 10-membered ring structures, more preferably 3- to 7-membered rings, whose ring structures include one to four heteroatoms. Heterocycles can also be polycycles. Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxathiin, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, perimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane, thiolane, oxazole, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. The heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF3, —CN, or the like.
  • Unless the number of carbons is otherwise specified, “lower alkyl” as used herein means an alkyl group, as defined above, but having from one to ten carbons, more preferably from one to six carbon atoms in its backbone structure. Likewise, “lower alkenyl” and “lower alkynyl” have similar chain lengths. Preferred alkyl groups are lower alkyls. In preferred embodiments, a substituent designated herein as alkyl is a lower alkyl.
  • As used herein, the term “nitro” means —NO2; the term “halogen” designates —F, —Cl, —Br or —I; the term “sulfhydryl” means —SH; the term “hydroxyl” means —OH; and the term “sulfonyl” means —SO2—.
  • The terms ortho, meta and para apply to 1,2-, 1,3- and 1,4-disubstituted benzenes, respectively. For example, the names 1,2-dimethylbenzene and ortho-dimethylbenzene are synonymous.
  • A “phosphoryl” can in general be represented by the formula:
    Figure US20070020384A1-20070125-C00006

    wherein Q1 represented S or O, and R46 represents hydrogen, a lower alkyl or an aryl. When used to substitute, e.g., an alkyl, the phosphoryl group of the phosphorylalkyl can be represented by the general formula:
    Figure US20070020384A1-20070125-C00007

    wherein Q1 represented S or O, and each R46 independently represents hydrogen, a lower alkyl or an aryl, Q2 represents O, S or N. When Q1 is an S, the phosphoryl moiety is a “phosphorothioate”.
  • “Plant” as used herein refers to any member of the plant kingdom, at any stage of its life cycle, including seeds, germinated seeds, seedlings, or mature plants.
  • “Plant cell” refers to a cell from a plant or plant component.
  • “Plant component” refers to a portion or part of a plant. Examples include: seeds, roots, stems, vascular systems, fruits (further including pip fruits (e.g. apples, pears, quinces)), citrus fruits (oranges, lemons, limes, grapefruits, mandarins, nectarines), stone fruits (peaches apricots, plums, cherrries, avocados, grapes), berries (strawberries, blueberries, raspberries, blackberries)), leaves, grains and vegetables.
  • A “plant pathogen” refers to an organism (bacteria, virus, protist, algae or fungi) that infects plants of plant components. Examples include molds, fungi and rot that typical use spores to infect plants or plant components (e.g fruits, vegetables, grains, stems, roots). Spores must recognize the host, attach, germinate, penetrate host tissues, and proliferate hyphae that will allow the fungus access to nutrients for growth and reproduction. Examples include: Botrytis sp. (B. cinerea), Penicillium sp. (P. expansum, P. italicum, P. digitalum), Rhizopus sp. (R. sulonifer, R. nigricans), Alternaria sp. (A. alternata, A. solani), Diploidia sp. (Diploidia natalenses), Monilinia sp. (M. fructicola), Pseudomonas sp. (P. cepacia) Xanthomonas sp., Erwinia sp. and Corynebacterium. Cladosporium sp. (C. fulva), Phytophtora sp. (P. infestans), Colletotricum spp. (C. coccoides C. fragariae, C. gloesporioides), Fusarium spp. (F. lycopersici), Verticillium spp. (V. alboatrum, V. dahliae), Unicula spp. (U. necator), Plasmopara spp. (P. viticola), Guignardia spp. (G. bidwellii), Cercospora spp. (C. arachidicola), Scelrotinia spp. (S. scerotiorum), Puccinia spp. (P. arachidis), Aspergillus spp. (A. flavus), Venturia spp (V. inaequalis) Podosphaera spp. (P. leucotricha), Pythiun spp., Sphaerotheca (S. macularis) and Bacillus spp. (B. subitlis).
  • A “polar, aprotic solvent” means a polar solvent as defined above which has no available hydrogens to exchange with the compounds of this invention during reaction, for example DMF, acetonitrile, diglyme, DMSO, or THF.
  • A “polar solvent” means a solvent which has a dielectric constant (e) of 2.9 or greater, such as DMF, THF, ethylene glycol dimethyl ether (DME), DMSO, acetone, acetonitrile, methanol, ethanol, isopropanol, n-propanol, t-butanol or 2-methoxyethyl ether. Preferred solvents are DMF, DME, NMP, and acetonitrile.
  • The terms “polycyclyl” or “polycyclic group” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”. Rings that are joined through non-adjacent atoms are termed “bridged” rings. Each of the rings of the polycycle can be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, —CF3, —CN, or the like.
  • The phrase “protecting group” as used herein means temporary modifications of a potentially reactive functional group which protect it from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991).
  • “Release rate” or “flux” refers to the rate of delivery or diffusion of a compound to and ultimately from a surface. The release rate may be constant or sustained over a period of time or may be variable. However, constant, controlled or sustained release rates are generally preferred. Steady state or sustained release may be effected by use of a reservoir membrane (i.e. a two layer coating in which one layer contains the active agent and the other creates a membrane through which the active agent can be released). The active agent could alternatively be microencapsulated within any of a variety of matrices for sustained release. Preferred release rates are in the range of about 100 to about 200 μgcm−2d−1 is useful for temporary uses of uses that require reapplication. For more sustained applications, preferred release rates are in the range of about 1 to about 100 μgcm−2d−1 , more preferably in the range of about 1-50 and still more preferably in the range of about 1-25 or better yet, 1-15.
  • The term “soluble” refers to the ability to be loosened or dissolved. A “solubilized” compound has been loosened or dissolved (e.g. into a fluid).
  • As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described hereinabove. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
  • It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.
  • The term “sulfate” is art recognized and includes a moiety that can be represented by the general formula:
    Figure US20070020384A1-20070125-C00008

    in which R41 is as defined above.
  • A “sulfate binding moiety” refers to a moiety that is capable of binding or otherwise associating with a sulfate or sulfonate group.
  • The term “sulfonate” is art recognized and includes a moiety that can be represented by the general formula:
    Figure US20070020384A1-20070125-C00009

    in which R41 is an electron pair, hydrogen, alkyl, cycloalkyl, or aryl.
  • The terms “sulfoxido” or “sulfinyl”, as used herein, refers to a moiety that can be represented by the general formula:
    Figure US20070020384A1-20070125-C00010

    in which R44 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aralkyl, or aryl.
  • Analogous substitutions can be made to alkenyl and alkynyl groups to produce, for example, aminoalkenyls, aminoalkynyls, amidoalkenyls, amidoalkynyls, iminoalkenyls, iminoalkynyls, thioalkenyls, thioalkynyls, carbonyl-substituted alkenyls or alkynyls.
  • The term “surface” as used herein, refers to any interface between an object and a fluid environment, which permits at least intermittent contact between the object and the fluid environment. Fluids contacting the surfaces can be stagnant or flowing, and can flow intermittently or continuously, with laminar or turbulent or mixed rheologies. A surface upon which a biofilm can form can be dry at times with sporadic fluid contact, or can have any degree of fluid exposure including total immersion. Fluid contact with the surface can take place via aerosols or other means for air-borne fluid transmission.
  • “Sustained release” or “controlled release refers to a relatively constant or prolonged release of a compound of the invention from a surface. This can be accomplished through the use of diffusional systems, including reservoir devices in which a core of a compound of the invention is surrounded by a porous membrane or layer, and also matrix devices in which the compound is distributed throughout an inert matrix. Microencapsulation techniques can also be used to maintain a sustained focal release of a compound of the invention. Microencapsulation may also be used for providing improved stability. The encapsulated product can take the form of for example, spheres, aggregates of core material embedded in a continuum of wall material, or capillary designs. The core material of a microcapsule containing a compound of the invention may be in the form of a liquid droplet, an emulsion, a suspension of solids, a solid particle, or a crystal. The skilled artisan will be aware of numerous materials suitable for use as microcapsule coating materials, including, but not limited to, organic polymers, hydrocolloids, lipids, fats, carbohydrates, waxes, metals, and inorganic oxides. Silicone polymers are the most preferred microcapsule coating material for treatment of surfaces. Microencapsulation techniques are well known in the art and are described in the Encyclopedia of Polymer Science and Engineering, Vol. 9, pp. 724 et seq. (1989) hereby incorporated by reference.
  • The abbreviations Me, Et, Ph, Tf, Nf, Ts, Ms, and dba represent methyl, ethyl, phenyl, trifluoromethanesulfonyl, nonafluorobutanesulfonyl, p-toluenesulfonyl, methanesulfonyl, and dibenzylideneacetone, respectively. A more comprehensive list of the abbreviations utilized by organic chemists of ordinary skill in the art appears in the first issue of each volume of the Journal of Organic Chemistry; this list is typically presented in a table entitled Standard List of Abbreviations. The abbreviations contained in said list, and all abbreviations utilized by organic chemists of ordinary skill in the art are hereby incorporated by reference.
  • For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover. Also for purposes of this invention, the term “hydrocarbon” is contemplated to include all permissible compounds having at least one hydrogen and one carbon atom. In a broad aspect, the permissible hydrocarbons include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic organic compounds which can be substituted or unsubstituted.
  • Compositions of the Invention
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1:
    Figure US20070020384A1-20070125-C00011

    wherein
  • X represents —OH, —O(aryl), —O(acyl), —O(sulfonyl), —CN, F, Cl, or Br;
  • Y represents O, S, Se, or NR;
  • Z represents optionally substituted alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or —(CH2)m—R80;
  • R represents independently for each occurrence hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, or —(CH2)m—R80;
  • R80 represents independently for each occurrence aryl, cycloalkyl, cycloalkenyl, heterocyclyl, or polycyclyl; and
  • m is an integer in the range 0 to 8 inclusive.
  • Particularly stable compounds are represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br.
  • In other preferred embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Y represents O.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Z represents optionally substituted alkyl, aryl, or —(CH2)m—R80.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein R represents H or alkyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; and Y represents O.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; and Y represents O.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; and Z represents optionally substituted alkyl, aryl, or —(CH2)m—R80.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; and Z represents optionally substituted alkyl, aryl, or —(CH2)m—R80.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; and Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; and Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; and Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; and Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(11,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Y represents O; and Z represents optionally substituted alkyl, aryl, or —(CH2)m—R80.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Y represents O; and Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein Y represents O; and Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(11,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; Y represents O; and Z represents optionally substituted alkyl, aryl, or —(CH2)m—R80.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; Y represents O; and Z represents optionally substituted alkyl, aryl, or —(CH2)m—R80.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; Y represents O; and Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; Y represents O; and Z represents optionally substituted alkylphenyl, heteroalkylphenyl, arylphenyl, or heteroarylphenyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH, F, Cl, or Br; Y represents O; and Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1,1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • In certain embodiments, the compositions of the present invention comprise an anti-fouling compound represented by general structure 1 and the attendant definitions, wherein X represents —OH or Cl; Y represents O; and Z represents methyl, octyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1,1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
  • One of skill in the art will recognize that the composition of the invention can be varied as required to optimize the overall chemical properties of the particular compound for specific uses, while retaining the activity. For example, the length of an alkyl chain can be extended or shortened to control the rate of dissolution of the compound from a structure or a coating. Alternatively, additional functional groups can be added to the alkyl chain to further vary the chemical nature of the molecule.
  • The present invention is further illustrated by the following examples, which should not be construed as limiting in any way. The contents of all cited references including literature references, issued patents and published patent applications as cited throughout this patent application are hereby expressly incorporated by reference.
  • EXAMPLES Example 1 Inhibition of Surface Attachment of C. fragariae by Zosteric Acid
  • In vitro evaluation of zosteric acid for disease control efficacy indicated that the sodium salt of zosteric acid was an effective non-toxic fungal control agent for Strawberry (cv. Chandler-susceptible variety) anthracnose caused by Colletotrichum fragariae. Detached leaf and petiole assays were employed to determine an effective dose. An optimum effective concentration of about 2% (which is within a range that is commercially viable) was obtained when the agent was applied in phosphate buffer (pH 7.0) containing 0.1% Tween 20, and when plant tissues were sprayed to wetness with a spore density of 1.5×106 spores/mL (FIG. 1).
  • Greenhouse evaluations of zosteric acid for efficacy in control of anthracnose crown rot of strawberry confirmed that the optimal concentration of zosteric acid was 2% for C. fragariae. It was found that the disodium salt of zosteric acid showed very low or no detectable phytotoxicity.
  • Spore attachment assays ascertained that the most effective analogs, where the sodium salt of zosteric acid and the TPPC analog (FIG. 3). The 1% zosteric acid prevented spores from germinating during the 24 hour incubation while the lower concentrations (0.1 and 0.01%) reduced the number of spores germinating (FIG. 4). Post-harvest treatment of ripe blueberries with zosteric acid sodium salt and a zosteric acid analog followed by innoculation with C. acutatum resulted in a decrease of about 50% in the number of infected berries in the 0.67 and 2% zosteric acid analog treatment.
  • Example 2 Inhibition of Surface Attachment of Marine Bacteria by Alkyl Sulfates
  • Octyl sulfate is an alkyl sulfate surfactant with extensive industrial applications, and is manufactured by several large chemical companies. To investigate potential AF properties of the sulfate ester octyl sulfate, it was incorporated into an inert coating material that was then coated onto a surface to be exposed to conditions that support the formation of marine algal biofilms.
  • Materials and Methods
  • A 30% (w/v) solution of octyl sulfate in water (Stepan Chemical Co.) was evaporated to dryness under a stream of room temperature air, to recover pure octyl sulfate (FIG. 5). The dry octyl sulfate was incorporated into RTV-11 silicone polymer at a loading of 25% (wt/wt) (RTV-11 silicone, catalyst and primer obtained from General Electric). The mixture was applied to three glass slides previously primed with silicone primer, and allowed to cure to dryness. Three primed glass slides coated with pure RTV-11 served as agent-free controls. After complete drying, the absorption properties of each slide were measured using a Shimadzu UV-2101 spectrophotometer fitted with an integrating sphere. Slides were then placed in a tank of running raw seawater and allowed to incubate outdoors in natural sunlight for 26 days. Water temperature was nominally 15 C. Spectrophotometric determination of biofilm accumulation was measured on each slide periodically. Relative algal biomass was calculated as the ratio of absorption at 680 nm, contributed by chlorophyll a, to that at 750 nm, a wavelength not absorbed by chlorophyll, to correct for differences in turbidity and scattering properties of the different slides.
  • Results
  • As shown in FIG. 5, octyl sulfate incorporated into RTV-11 silicone, and then coated onto glass slides, significantly inhibited the formation of natural marine algal biofilms in natural seawater. After 26 days of incubation in running seawater, algal biofilm development on the octyl sulfate containing coatings was five fold less than that of controls lacking octyl sulfate, indicating that octyl sulfate possesses strong AF activity.
  • Studies were performed to evaluate the ability of the sulfate ester molecules octyl sulfate and methyl sulfate, to inhibit adhesion of the marine bacteriums Oceanosprillum and Alteromonas atlantica to glass surfaces.
  • Materials and Methods
  • Oceanosprillum adhesion test Each test consisted of a control set (with no sulfate esters) and sample sets containing the test molecules. The first test group consisted of a control sample set, a zosteric acid (5 mM) sample set, and an octyl sulfate (5 mM) sample set. The second test group consisted of a control sample set, a zosteric acid (5 mM) sample set, and a methyl sulfate (5 mM) sample set. Sample sets consisted of five 50 mL sterile centrifuge tubes, with each tube containing a glass microscope slide, 50 ml of artificial seawater (ASTM—American Society for testing and materials) with the dissolved sulfate ester, inoculated with an Oceanosprillum culture at 1×106 cells/mL. Sample sets were incubated at 23 C, with shaking so that the surface of the slides were horizontal. Over a 6-hour period, individual tubes were taken from the sample sets and tested for microbial adhesion.
  • Alteromonas atlantica adhesion tests. The tests consisted of a control sample set, a zosteric acid (5 mM) sample set, an octyl sulfate (5 mM) sample set, and a methyl sulfate (5 mM) set. A sample set consisted of six 60 mL sterile centrifuge tubes. Each tube contained a glass microscope slide and 50 mL of modified ASTM seawater (American Society for Testing and Materials (1986) D1141-86, ASTM, Philadelphia, Pa.) with dissolved agent, inoculated with Alteromonas atlantica culture to an initial cell density of 1×106 cells/mL. The modified seawater consisted of normal ASTM seawater ingredients, however-the carbon source glycerol, was only 1000th the normal strength, 0.1 L/L instead of 100 L/L, and was void of an amino acid source (casamino acids), in order to allow enough carbon for attachment, but not for significant cell growth.
  • Determination of bacterial adhesion. Samples were removed from the shaker and 1 mL of 50× acridine orange stain (0.5 g/L acridine powder in water) was added to the tube. The stain was allowed to react for 4 minutes. The slides were then removed and fitted with a long cover slip and immediately counted with an epifluorescent microscope fitted with a 100× (oil) objective lens on the under side of the slide. The size of the counting field was 10×10 μm. A total of 20 counts per slide were performed and averaged to yield the number of cells per μm2, which was in turn converted to cells per mm2. Error was assigned at 10% which is the standard accepted error for direct counting of bacterial cells.
  • Results
  • As shown in FIG. 6, the presence of octyl sulfate or methyl sulfate in the medium significantly reduced bacterial adhesion to the glass slides when compared to controls in which no sulfate ester molecule was present. Methyl sulfate inhibited Oceanosprillum adhesion to an extent similar to the proven AF agent zosteric acid, with each compound promoting roughly a two fold reduction in bacterial attachment, relative to control. As shown in FIG. 4, octyl sulfate inhibited Oceanosprillum adhesion to an even greater extent than zosteric acid.
  • As shown in FIG. 8, the presence of dissolved zosteric acid, octyl sulfate, or methyl sulfate produced a significant reduction in the marine bacterium, Alteromonas atlantica adhesion relative the controls. The presence of methyl sulfate had the most dramatic effect upon adhesion, with adhesion remaining constant after 120 minutes at 150,000 cells/mm2, while controls had greater than 700,000 cells/mm2. Octyl sulfate also inhibited adhesion, demonstrating a slightly higher inhibitory activity than zosteric acid.
  • Example 3 Inhibition of Fungal Surface Attachment and Mycelial Development
  • To determine the effectiveness of sulfate esters at inhibiting fungal biofouling, the ability of zosteric acid to inhibit attachment of the fungus Aureobasidium pullulans to surfaces was examined.
  • Materials and Methods
  • Aureobasidium pullulans (ATCC 34261) was grown on potato-dextrose agar and harvested according to ASTM G-2 1-90 protocols (American Society for Testing and Materials (1986) D1141-86, ASTM, Philadelphia, Pa.). The resulting spore suspension was used to inoculate liquid culture tubes containing 35 mL of growth medium (nutrient salts with 5 mM sucrose) and 15 mM zosteric acid. Zosteric acid-free medium was prepared as a control. A sterile microscope slide was added to each tube, the tubes were sealed and placed on a rotary shaker table at room temperature. One tube was harvested each day by removing the slide and counting the number of attached spores by direct microscopic counts, as described above.
  • Results
  • Fungal spores were observed to grow in both the presence and absence of zosteric acid, as indicated by the clouding of all tubes after Day 1. However, as shown in FIG. 9, the presence of zosteric acid prevented the attachment of the fungus to the glass slides. After 5 days incubation with A. pullalans, less than 20 germinated fungal colonies/mm2 were observed on slides incubated in the additional presence of zosteric acid, compared to more than 600 germinated fungal colonies/mm2 on control slides. Furthermore, fungal colonies in the media of zosteric acid free cultures were composed of multi-cellular (>20 cells) filaments, indicative of mycelial growth. In contrast, colonies in the zosteric acid treated cultures were generally small and round, exhibiting no evidence of filamentous growth or mycelial development.
  • Example 4 Sulfate Esters Bind Cell Surfaces of Shewanella putrefaciens
  • To investigate the mechanism behind the AF activity of sulfate esters, polyclonal antibodies specific for the sulfate ester zosteric acid were generated (BAbCo, Berkeley, CA). Preliminary testing of these antibodies for cross reactivity towards related compounds lacking the sulfate ester group (cinnamic acid, ferulic acid, coumaric acid) showed no cross reactivity, suggesting that the specific domain recognized by the antibodies probably includes the sulfate ester group. These antibodies were then used to investigate whether the sulfate ester AF agent zosteric acid directly binds fouling organisms.
  • The marine bacterium Shewanella putrefaciens were grown in cultures containing zosteric acid and were subsequently examined for bound zosteric acid using immuno-gold staining with the antibody described above. Electron microscopic examination of immunoprobed S. putrefaciens detected zosteric acid molecules bound to the surface of the bacteria. Furthermore, zosteric acid was observed to be present at high incidence at the sites of cell adhesion. In contrast to these agglutination sites, the majority of the cell surfaces as well as the continuous boundaries between daughter cells in dividing chains, showed no evidence of bound zosteric acid, as indicated by a lack of immuno-gold staining. These results indicate that sulfate esters bind to the surfaces of bacterial cells and suggest a possible relationship between sulfate ester binding sites and the sites of bacterial agglutination.
  • Example 5 Zosteric Acid Promotes Bacterial Agglutination
  • To further investigate the role of sulfate esters in agglutination, the ability of sulfate esters to facilitate the agglutination of bacterial cells was investigated. Log-phase cultures grown in the presence of zosteric acid were monitored spectrophotometrically (OD600) for growth, and for agglutination in the presence of increasing amounts of zosteric acid.
  • Materials and Methods
  • Cell Surface Binding Assays. The marine bacterium Shewanella putrefaciens was grown in marine broth in the presence of 16 mM zosteric acid. Dense log phase cells were harvest after 5 hours growth, and preserved in 0.5× Kamofsky's fixative (2% formaldehyde, 2.5% gluturaldehyde, 0.05 M sodium cacodylate, 0.25 M sucrose, pH 7.4) for 2 hours, and then transferred to a cacodylate buffer (0.05 M sodium cacodylate, pH 7.4) for storage. Cells were prepared for electron microscopic examination using immuno-gold staining techniques (Harlow, E. and Laine, D., Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, 359-421; Roth et al., J. Histochem. Cytochem. 26: 1074-1081 (1978)). The primary antibody used in this study was an anti-zosteric acid polyclonal antibody (BAbCo, Richmond, Calif.).
  • Bacterial agglutination assays. Log-phase cultures of Shewanella putrefaciens were grown in complete seawater medium containing zosteric acid at a range of concentrations up to 20 mM. Cultures were counted for viable colony forming units at eight hours.
  • Results
  • Although zosteric acid concentrations up to 16 mM did not inhibit the growth of S. putrefaciens in liquid culture, the presence of zosteric acid caused significant agglutination of S. putrefaciens in a concentration dependent manner. The agglutination observed was visible to the naked eye, and was more quantitatively detected as a decrease in optical density absorbance in cultures containing zosteric acid (FIG. 10). Counts of viable colony forming units at eight hours revealed no difference in cell density among the different cultures, thus the observed differences in absorption resulted from differences in bacterial agglutination, not differences in growth (cell division) rates among the cultures. Thus, zosteric acid promoted cell agglutination, but did not
  • EQUIVALENTS
  • Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are encompassed by the following claims.

Claims (20)

1-70. (canceled)
71. A method of preventing fouling on a plant surface comprising contacting the plant surface with an effective amount of an anti-fouling compound represented by general structure 1:
Figure US20070020384A1-20070125-C00012
wherein
X represents —OH, F, Cl, or Br;
Y represents O, S, or NR;
Z represents optionally substituted alkyl, aryl, heteroaryl, or aralkyl; and
R represents independently for each occurrence hydrogen, alkyl, or aryl.
72. The method of claim 71, wherein X is OH or Cl.
73. The method of claim 71, wherein Y is O.
74. The method of claim 71, wherein Z is alkyl.
75. The method of claim 71, wherein Z is aryl.
76. The method of claim 71, wherein X is OH or Cl, and Y is O.
77. The method of claim 71, wherein X is OH or Cl, Y is O, and Z is alkyl.
78. The method of claim 71, wherein X is OH or Cl, Y is O, and Z is aryl.
79. The method of claim 71, wherein Z is methyl, n-octyl, phenyl, 4-(2-methylpropyl)phenyl, 4-(1,1-dimethylethyl)phenyl, 4-(1,1-dimethylpropyl)phenyl, 4-pentylphenyl, 4-(1-methyl-1-phenylethyl)phenyl, or 4-(1-methylheptyl)phenyl.
80. The method of claim 71, wherein X is OH, Y is O, and Z is methyl.
81. The method of claim 71, wherein X is OH, Y is O, and Z is n-octyl.
82. The method of claim 71, wherein X is OH, Y is O, and Z is phenyl.
83. The method of claim 71, wherein X is Cl, Y is O, and Z is 4-t-butylphenyl.
84. The method of claim 71, wherein X is Cl, Y is O, and Z is 4-t-pentylphenyl.
85. The method of claim 71, wherein the anti-fouling compound is dissolved or dispersed in a medium.
86. The method of claim 85, wherein the medium comprises an organic polymer, hydrocolloids, lipid, fat, carbohydrate, wax, inorganic oxide, or silicone polymer.
87. The method of claim 85, wherein the medium is an aqueous medium.
88. The method of claim 71, wherein contacting the surface comprises spraying, wetting, immersing, dipping, or painting the surface.
89. The method of claim 71, wherein the plant surface is crop surface.
US11/475,833 1998-09-23 2006-06-27 Environmentally benign crop protection agents Abandoned US20070020384A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/475,833 US20070020384A1 (en) 1998-09-23 2006-06-27 Environmentally benign crop protection agents

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15981498A 1998-09-23 1998-09-23
US9405299A 1999-09-23 1999-09-23
US11/475,833 US20070020384A1 (en) 1998-09-23 2006-06-27 Environmentally benign crop protection agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/405,299 Continuation US7108861B1 (en) 1998-09-23 1999-09-23 Environmentally benign crop protection agents

Publications (1)

Publication Number Publication Date
US20070020384A1 true US20070020384A1 (en) 2007-01-25

Family

ID=22574162

Family Applications (4)

Application Number Title Priority Date Filing Date
US09/405,299 Expired - Fee Related US7108861B1 (en) 1998-09-23 1999-09-23 Environmentally benign crop protection agents
US09/405,269 Expired - Fee Related US7087661B1 (en) 1998-09-23 1999-09-23 Safe and effective biofilm inhibitory compounds and health-related uses thereof
US11/475,833 Abandoned US20070020384A1 (en) 1998-09-23 2006-06-27 Environmentally benign crop protection agents
US11/475,548 Abandoned US20070020309A1 (en) 1998-09-23 2006-06-27 Safe and effective biofilm inhibitory compounds and health related uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/405,299 Expired - Fee Related US7108861B1 (en) 1998-09-23 1999-09-23 Environmentally benign crop protection agents
US09/405,269 Expired - Fee Related US7087661B1 (en) 1998-09-23 1999-09-23 Safe and effective biofilm inhibitory compounds and health-related uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/475,548 Abandoned US20070020309A1 (en) 1998-09-23 2006-06-27 Safe and effective biofilm inhibitory compounds and health related uses thereof

Country Status (8)

Country Link
US (4) US7108861B1 (en)
EP (4) EP1115284A1 (en)
JP (4) JP2002526184A (en)
AU (4) AU6264099A (en)
BR (4) BR9913912A (en)
CA (4) CA2345232A1 (en)
IL (8) IL142132A0 (en)
WO (4) WO2000016632A2 (en)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713297B2 (en) 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
CA2345232A1 (en) * 1998-09-23 2000-03-30 Phycogen, Inc. Environmentally benign crop protection agents
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
AU2001253147A1 (en) * 2000-04-03 2001-10-15 Phycogen, Inc. Generation of combinatorial synthetic libraries and screening for proadhesins and nonadhesins
CA2411944C (en) 2000-06-09 2010-12-14 Baylor College Of Medicine The combination of antimicrobial agents and bacterial interference to coat medical devices
WO2002072020A2 (en) * 2001-03-12 2002-09-19 Cerno Biosciences, Llc. Novel anti-adhesive compounds and uses thereof
JP5143982B2 (en) * 2001-05-08 2013-02-13 エヌディー パートナーズ,リミティド ライアビリティー カンパニー Biocide lock
DE10207174A1 (en) * 2002-02-20 2003-08-21 Doetsch Jutsch Christel Topical or systemic medicaments for use in human and/or veterinary medicines for the treatment of bacterial or viral infections, comprises extracts of Zosteraceae family marine plants
AU2003218628B2 (en) * 2002-04-30 2005-11-24 Technical University Of Denmark Composition and method for controlling microbial adhesion and biofilm formation of surfaces
US20060029640A1 (en) * 2004-08-05 2006-02-09 Gilbert Jeremy L Medical devices with surface modification for regulating cell growth on or near the surface
GB0502046D0 (en) * 2005-02-01 2005-03-09 Sinclair Pharmaceuticals Ltd Method
AR056290A1 (en) * 2005-03-31 2007-10-03 Nippon Soda Co METHOD FOR INHIBITING THE PRODUCTION OF MICOTOXIN
US20070224235A1 (en) 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
CA2655793A1 (en) 2006-06-29 2008-01-03 Boston Scientific Limited Medical devices with selective coating
WO2008009067A1 (en) * 2006-07-20 2008-01-24 Newsouth Innovations Pty Limited Antifouling coating
EP2068757B1 (en) 2006-09-14 2011-05-11 Boston Scientific Limited Medical devices with drug-eluting coating
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US7906544B2 (en) * 2007-01-26 2011-03-15 North Carolina State University Inhibition of bacterial biofilms with imidazole derivatives
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8573218B2 (en) 2007-03-07 2013-11-05 Michael John RUTTER Tracheostomy tube
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US8513305B2 (en) 2007-05-14 2013-08-20 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
CA2687031A1 (en) 2007-05-15 2008-11-20 Chameleon Biosurfaces Limited Polymer coatings on medical devices
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US20110041725A1 (en) * 2007-06-19 2011-02-24 Daniel Rittschof Anticoagulants as antifouling agents
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
DE102007032686A1 (en) * 2007-07-13 2009-01-15 Biotronik Vi Patent Ag Stent with a coating
US9284409B2 (en) * 2007-07-19 2016-03-15 Boston Scientific Scimed, Inc. Endoprosthesis having a non-fouling surface
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
WO2009018340A2 (en) 2007-07-31 2009-02-05 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
EP2185103B1 (en) 2007-08-03 2014-02-12 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US20090041727A1 (en) 2007-08-08 2009-02-12 Conjugon, Inc. Compositions and Methods for Microbe Storage and Delivery
DE102007042451A1 (en) * 2007-09-06 2009-03-12 Biotronik Vi Patent Ag Stent with a body made of a biocorrodible alloy
CA2700256C (en) * 2007-09-20 2020-09-22 Tel Hashomer Medical Research Infrastructure And Services Ltd. Sessile cnidarian composition for prevention of bacteria adhesion and methods of using same
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8278340B2 (en) * 2007-11-27 2012-10-02 North Carolina State University Inhibition of biofilms in plants with imidazole derivatives
WO2009123753A1 (en) * 2008-04-04 2009-10-08 North Carolina State University Inhibition of bacterial biofilms with imidazole-phenyl derivatives
WO2009131654A2 (en) 2008-04-21 2009-10-29 North Carolina State University Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives
JP5581311B2 (en) 2008-04-22 2014-08-27 ボストン サイエンティフィック サイムド,インコーポレイテッド MEDICAL DEVICE HAVING INORGANIC MATERIAL COATING AND MANUFACTURING METHOD THEREOF
WO2009132176A2 (en) 2008-04-24 2009-10-29 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US9072292B2 (en) * 2008-06-06 2015-07-07 T. Brian Cavitt Biofilm resistant polymer materials
US8449603B2 (en) 2008-06-18 2013-05-28 Boston Scientific Scimed, Inc. Endoprosthesis coating
JP4491514B1 (en) 2008-10-21 2010-06-30 株式会社メニコン Contact lens storage container
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
WO2010077603A1 (en) 2008-12-08 2010-07-08 North Carolina State University Inhibition and dispersion of biofilms in plants with imidazole-triazole derivatives
EP3695835A1 (en) 2009-02-03 2020-08-19 Microbion Corporation Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications
US9028878B2 (en) 2009-02-03 2015-05-12 Microbion Corporation Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
AU2010216050B2 (en) * 2009-02-17 2013-07-18 Mcalister Technologies, Llc Electrolytic cell and method of use thereof
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese
WO2010144686A1 (en) 2009-06-10 2010-12-16 North Carolina State University Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives
KR20200015814A (en) * 2010-02-03 2020-02-12 마이크로비온 코포레이션 Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses
WO2012135016A2 (en) 2011-03-25 2012-10-04 North Carolina State University Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
JP5379192B2 (en) * 2011-07-01 2013-12-25 エヌディー パートナーズ,リミティド ライアビリティー カンパニー Biocide lock
US9033956B2 (en) 2011-09-06 2015-05-19 Cook Medical Technologies Llc Electrically charged medical device
US10016380B2 (en) * 2013-05-01 2018-07-10 Lanny Leo Johnson Antimicrobials and methods of use thereof
EP2803372A1 (en) 2013-05-16 2014-11-19 Universiteit Twente Process for the preparation of an object supporting a lipid bilayer
US9763814B2 (en) 2014-10-24 2017-09-19 Cook Medical Technologies Llc Elongate medical device
CN105104026B (en) * 2015-07-23 2018-07-17 中国农业大学 Using the method for administration of vanillic aldehyde prevention Meloidogyne incognita under edaphic condition
EP3487500A4 (en) * 2016-02-29 2020-06-24 Aequor, Inc. Antimicrobial compounds and methods of use
AU2017233547B2 (en) * 2016-03-17 2022-03-03 Tekcyte Limited Anti-fouling and/or anti-thrombotic medical devices
US10513567B2 (en) 2016-05-31 2019-12-24 Georgia Tech Research Corporation Polycations and methods of making and using thereof
AU2017393322B2 (en) 2017-01-10 2020-07-09 Unilever Global Ip Limited Biofilm targeting microcapsule carrying a non-volatile functional material
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
KR20210080350A (en) 2018-07-31 2021-06-30 마이크로비온 코포레이션 Bismuth-thiol compositions and methods for wound treatment
JP2021533193A (en) 2018-07-31 2021-12-02 マイクロビオン コーポレーション Bismuth thiol composition and usage
KR102282017B1 (en) * 2019-06-05 2021-07-29 주식회사 오아이디 Coating structure of orthopedic endoprosthesis and method for modifying orthopedic endoprosthesis surface
WO2024074495A1 (en) * 2022-10-04 2024-04-11 Cysbio Aps Method to inhibit proliferation of a phytopathogen on plants and compositions used for this purpose

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141821A (en) * 1959-03-17 1964-07-21 Lehn & Fink Products Corp Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5821300A (en) * 1996-11-07 1998-10-13 Witco Gmbh Process for preparing polymeric binders and their use for antifouling paint systems
US5914357A (en) * 1995-09-08 1999-06-22 Nippon Paint Co., Ltd. Hydrolyzable resin containing aldehyde bounded thereto and self-polishing antifouling paint
US5919840A (en) * 1996-08-22 1999-07-06 Elf Atochem, S.A. (Meth) acrylic resin compositions for marine antifouling paints and corresponding paint compositions
US6103131A (en) * 1997-07-29 2000-08-15 Buckman Laboratories International Inc. Methods for controlling biofouling using sulfamic acids
US6177530B1 (en) * 1997-05-20 2001-01-23 Mitsubishi Rayon Co., Ltd. Antifouling paint composition
US6291549B1 (en) * 1996-10-24 2001-09-18 Bayer Aktiengesellschaft Antifouling paints
US6365066B1 (en) * 1996-10-24 2002-04-02 Bayer Aktiengesellschaft Antifouling paint
US6433076B1 (en) * 1997-07-24 2002-08-13 Sk Kaken Co., Ltd. Low-staining agent for aqueous paint, low-staining aqueous paint composition, and process for use thereof

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE624917A (en) *
FR1696E (en) * 1903-01-30 1903-09-04 Frederic Jean Max Hilbig Safety stop for umbrellas, walking sticks, cycles, etc.
GB207250A (en) 1922-08-21 1923-11-21 William Henry Peck An improved clip for supporting articles on the hand
US2190733A (en) * 1937-07-26 1940-02-20 Du Pont Manufacture of alkyl substituted aryl sulphates
US3017421A (en) * 1959-04-27 1962-01-16 Du Pont Fluorine-containing compounds and process for preparing them
US3133949A (en) * 1960-07-01 1964-05-19 Exxon Research Engineering Co Novel preparation of organic sulfates
FR1696M (en) * 1961-11-25 1963-02-11 Philippe Serviere Ammonium or amine salts of fatty alcohol esters with mineral acids, which can be used in particular as bactericides.
US3632416A (en) * 1967-10-27 1972-01-04 Nat Patent Dev Corp Fibrous textile materials impregnated with hydroxyalkyl methacrylate casting syrups
US3681423A (en) * 1969-08-11 1972-08-01 Allied Chem Novel fluoroalkyl chlorosulfates and a method for their preparation
GB1457590A (en) * 1974-04-03 1976-12-08 Int Paint Co Marine paint
US3959206A (en) * 1974-10-21 1976-05-25 The Southland Corporation High molecular weight butadiene-styrene latex can end sealant composition
GB1470465A (en) * 1975-01-20 1977-04-14 Int Paint Co Coated marine surfaces
US4053610A (en) * 1975-03-10 1977-10-11 American Cyanamid Company 1,2-dialkyl-3(or 3,5)-n-heterocyclic pyrazolium salts or derivatives thereof as fungicidal agents
CH619482A5 (en) * 1975-10-17 1980-09-30 Biomarine Handel Paint for underwater surfaces
US4046731A (en) 1976-05-13 1977-09-06 Monsanto Company Process for preparing dopes from which shaped articles of oxadiazole/N-alkylhydrazide copolymers are obtained
US4227929A (en) * 1976-08-26 1980-10-14 Ameron, Inc. Siloxane-tin coatings
US4080190A (en) * 1976-08-26 1978-03-21 Ameron, Inc. Siloxane-tin coatings and their use for protecting materials from growth of pestiferous organisms
US4298543A (en) * 1976-08-26 1981-11-03 Ameron, Inc. Siloxane-tin coatings
GB1539771A (en) * 1976-09-01 1979-02-07 Quinoderm Ltd Dermatological compositions
US4191579A (en) * 1976-10-18 1980-03-04 The International Paint Company Limited Antifouling paint comprising a copolymer containing organo tin salt and a pigment having a component which reacts with sea water and another component which does not react with sea water
GB1589517A (en) * 1976-11-16 1981-05-13 Int Paint Co Marine paint
FR2398797B1 (en) * 1977-07-26 1981-02-06 Albright & Wilson CONCENTRATED AQUEOUS SURFACTANT COMPOSITIONS
US4222291A (en) * 1978-06-12 1980-09-16 Murphy Jr Patrick J Conical roller chain indexing device
US4240163A (en) * 1979-01-31 1980-12-23 Galin Miles A Medicament coated intraocular lens
JPS55111403A (en) * 1979-02-21 1980-08-28 Rikagaku Kenkyusho Antimicrobial for agriculture and horticulture
US4281110A (en) 1979-04-12 1981-07-28 Blount David H Process for the production of broken down lignin-cellulose silicate copolymers
SU858601A1 (en) * 1980-01-30 1981-08-30 Московская Ордена Ленина И Ордена Трудового Красного Знамени Сельскохозяйственная Академия Им.К.А.Тимирязева Potato planting method
US4261915A (en) * 1980-02-19 1981-04-14 Ameron, Inc. Siloxane-tin coatings
JPH0229644B2 (en) * 1980-02-27 1990-07-02 Maruzen Oil Co Ltd BOKABI * SATSUKINZAI
US4407997A (en) * 1980-10-29 1983-10-04 The International Paint Company Limited Marine paint
US4311629A (en) * 1980-11-12 1982-01-19 Ameron, Inc. Method for making antifouling coating composition containing hydrolyzed organotin siloxane polymer
GB2099444B (en) * 1981-05-29 1984-08-01 Berger Jenson & Nicholson Ltd Anti-fouling compositions
US4426464A (en) * 1981-07-03 1984-01-17 International Paint Public Limited Company Marine paint
US4385134A (en) * 1981-10-19 1983-05-24 Ameron, Inc. Organotin polysiloxane and acrylic antifouling coating
DE3229097A1 (en) * 1982-08-04 1984-02-09 Schülke & Mayr GmbH, 2000 Hamburg Microbicidal agents
US4605564A (en) 1984-01-23 1986-08-12 Biological & Environmental Control Laboratories, Inc. Coating process for making antimicrobial medical implant device
GB8414675D0 (en) * 1984-06-08 1984-07-11 Int Paint Plc Marine antifouling paint
GB8507048D0 (en) * 1985-03-19 1985-04-24 Int Paint Plc Paint
GB8511144D0 (en) * 1985-05-02 1985-06-12 Int Paint Plc Marine anti-fouling paint
GB8512212D0 (en) * 1985-05-14 1985-06-19 Int Paint Plc Binder for anti-fouling paints
US4670481A (en) * 1986-02-14 1987-06-02 Ameron, Inc. Organotin acrylate and organotin polysiloxane antifouling coating composition
US4895566A (en) 1986-07-25 1990-01-23 C. R. Bard, Inc. Coating medical devices with cationic antibiotics
US4908061A (en) * 1986-11-13 1990-03-13 Kansai Paint Co., Ltd. Antifouling coating
US4820525A (en) * 1987-09-17 1989-04-11 American Home Products Corporation (Del.) Transdermal drug delivery system
GB2213744B (en) * 1987-12-17 1991-09-18 Courtaulds Films & Packaging Production of polymeric films
US4947785A (en) * 1988-01-07 1990-08-14 International Paint Public Limited Company Improvements in or relating to boat hulls
US5019096A (en) 1988-02-11 1991-05-28 Trustees Of Columbia University In The City Of New York Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same
GB8803458D0 (en) * 1988-02-15 1988-03-16 Int Paint Plc Inhibition of marine fouling
FR2628746B1 (en) 1988-03-21 1992-03-27 Solvay PROCESS FOR THE PREPARATION OF A POLYPYRROLE-BASED LATEX AND USE OF THIS LATEX TO FORM A CONDUCTIVE FILM
JP2595678B2 (en) * 1988-04-15 1997-04-02 ダイキン工業株式会社 Antifouling paint composition and coated product
US5236493A (en) * 1988-10-13 1993-08-17 Courtaulds Coatings (Holdings) Limited Antifouling coating
US5008146A (en) * 1988-11-04 1991-04-16 Cape Cod Research, Inc. Zinc-carbon antifouling coating
GB2233251B (en) * 1989-06-20 1993-03-10 Courtaulds Films & Packaging Production of polymeric films
US5089205A (en) 1989-09-25 1992-02-18 Becton, Dickinson And Company Process for producing medical devices having antimicrobial properties
GB9014564D0 (en) * 1990-06-29 1990-08-22 Courtaulds Coatings Holdings Coating compositions
EP0626854B1 (en) 1990-07-12 1998-07-15 STS Biopolymers, Inc. Anti-thrombogenic and/or anti-microbial composition
US5057533A (en) * 1990-07-26 1991-10-15 Hodogaya Chemical Co., Ltd. Agricultural or horticultural fungicide
ATE214592T1 (en) * 1990-12-21 2002-04-15 Felice Bombart AQUEOUS VAGINAL DOUCHER AND ITS USE
CA2059245C (en) * 1991-02-08 2004-07-06 Michael P. Chesterfield Method and apparatus for calendering and coating/filling sutures
JPH0662442B2 (en) * 1991-03-06 1994-08-17 和彦 土蔵 Nasal drops
US5366665A (en) * 1991-07-30 1994-11-22 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising alkyl sulfooxyalkanoate compounds containing a beneficial reagent component
US5143545A (en) * 1991-09-20 1992-09-01 The United States Of America As Represented By The Secretary Of The Navy Antifouling marine coatings
US5663215A (en) * 1991-12-20 1997-09-02 Courtaulds Coatings (Holdings) Limited Coating compositions
JP3196361B2 (en) * 1991-12-25 2001-08-06 日立化成工業株式会社 Resin composition for paint and antifouling paint for underwater structures
US5304236A (en) * 1992-04-22 1994-04-19 Fears Clois D Composition of matter for lining, coating or manufacturing underwater structures to prevent living marine organisms adhering to or building up on exposed surfaces
US5681575A (en) 1992-05-19 1997-10-28 Westaim Technologies Inc. Anti-microbial coating for medical devices
US5284682A (en) * 1992-09-03 1994-02-08 American Marine Coatings, Inc. Copper/nickel epoxy coating and application process as antifouling agent
US5609874A (en) * 1992-09-07 1997-03-11 Virostat (Na) Nvq Method of treating viral infections
US5259701A (en) * 1992-10-22 1993-11-09 Rohm And Haas Company Antifouling coating composition comprising furan compounds, method for protecting aquatic structures, and articles protected against fouling organisms
US5248221A (en) * 1992-10-22 1993-09-28 Rohm And Haas Company Antifouling coating composition comprising lactone compounds, method for protecting aquatic structures, and articles protected against fouling organisms
US5688516A (en) 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5384176A (en) * 1992-12-11 1995-01-24 Zimmerman; Richard C. Phenolic acid sulfate esters for prevention of marine biofouling
US5436008A (en) * 1992-12-11 1995-07-25 Ecolab Inc. Sanitizing compositions
US5354603A (en) * 1993-01-15 1994-10-11 Minnesota Mining And Manufacturing Company Antifouling/anticorrosive composite marine structure
US5328954A (en) 1993-04-16 1994-07-12 Icet, Inc. Encrusting and bacterial resistant coatings for medical applications
AU1432595A (en) * 1993-12-09 1995-06-27 Research Foundation Of The State University Of New York, The Aquatic antifouling compositions and methods
US5403390A (en) * 1994-03-11 1995-04-04 Spera; Richard J. Cuprous sulfide marine antifoulant paint
US5397385A (en) * 1994-03-28 1995-03-14 Watts; James L. Anti-fouling coating composition containing capsaicin
GB9419668D0 (en) 1994-09-28 1994-11-16 Diversey Corp Disinfectant compositions
US5624704A (en) 1995-04-24 1997-04-29 Baylor College Of Medicine Antimicrobial impregnated catheters and other medical implants and method for impregnating catheters and other medical implants with an antimicrobial agent
US5521012A (en) * 1995-05-15 1996-05-28 Courtaulds Coatings Storage stable, water borne, zinc containing coatings
CA2185056A1 (en) 1995-09-08 1997-03-09 You Ling Fan Biostatic coatings and processes
US5756145A (en) 1995-11-08 1998-05-26 Baylor College Of Medicine Durable, Resilient and effective antimicrobial coating for medical devices and method of coating therefor
US5833963A (en) * 1996-08-20 1998-11-10 Bristol-Myers Squibb Company Non-tacky and quick-drying aqueous-based antiperspirant compositions
AU4063197A (en) 1996-09-04 1998-03-26 Kimberly-Clark Worldwide, Inc. Antimicrobial medical devices and methods of production and use
DE19654642C2 (en) * 1996-12-28 2003-01-16 Chemetall Gmbh Process for treating metallic surfaces with an aqueous solution
EP0852952A2 (en) * 1997-01-03 1998-07-15 Hüls Aktiengesellschaft Bioactive coating of surfaces
EP0860213A3 (en) * 1997-01-03 2002-10-16 Therapol SA Bioactive coating on surfaces
US5877243A (en) 1997-05-05 1999-03-02 Icet, Inc. Encrustation and bacterial resistant coatings for medical applications
CA2345232A1 (en) * 1998-09-23 2000-03-30 Phycogen, Inc. Environmentally benign crop protection agents
US6291357B1 (en) * 1999-10-06 2001-09-18 Applied Materials, Inc. Method and apparatus for etching a substrate with reduced microloading

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141821A (en) * 1959-03-17 1964-07-21 Lehn & Fink Products Corp Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5914357A (en) * 1995-09-08 1999-06-22 Nippon Paint Co., Ltd. Hydrolyzable resin containing aldehyde bounded thereto and self-polishing antifouling paint
US5919840A (en) * 1996-08-22 1999-07-06 Elf Atochem, S.A. (Meth) acrylic resin compositions for marine antifouling paints and corresponding paint compositions
US6291549B1 (en) * 1996-10-24 2001-09-18 Bayer Aktiengesellschaft Antifouling paints
US6365066B1 (en) * 1996-10-24 2002-04-02 Bayer Aktiengesellschaft Antifouling paint
US5821300A (en) * 1996-11-07 1998-10-13 Witco Gmbh Process for preparing polymeric binders and their use for antifouling paint systems
US6177530B1 (en) * 1997-05-20 2001-01-23 Mitsubishi Rayon Co., Ltd. Antifouling paint composition
US6433076B1 (en) * 1997-07-24 2002-08-13 Sk Kaken Co., Ltd. Low-staining agent for aqueous paint, low-staining aqueous paint composition, and process for use thereof
US6103131A (en) * 1997-07-29 2000-08-15 Buckman Laboratories International Inc. Methods for controlling biofouling using sulfamic acids

Also Published As

Publication number Publication date
US20070020309A1 (en) 2007-01-25
WO2000016624A1 (en) 2000-03-30
BR9914498A (en) 2001-06-26
US7087661B1 (en) 2006-08-08
WO2000016623A1 (en) 2000-03-30
CA2345231C (en) 2009-12-22
IL142131A0 (en) 2002-03-10
BR9914036A (en) 2001-06-12
EP1115289A2 (en) 2001-07-18
IL142132A (en) 2006-10-31
EP1115394A2 (en) 2001-07-18
EP1115284A1 (en) 2001-07-18
IL142132A0 (en) 2002-03-10
WO2000016632A3 (en) 2000-06-22
US7108861B1 (en) 2006-09-19
IL142129A0 (en) 2002-03-10
CA2345231A1 (en) 2000-03-30
AU6264099A (en) 2000-04-10
IL142130A (en) 2006-12-10
WO2000016632A2 (en) 2000-03-30
IL142131A (en) 2006-07-05
EP1115285A1 (en) 2001-07-18
JP2002526053A (en) 2002-08-20
JP2002526444A (en) 2002-08-20
AU6261499A (en) 2000-04-10
WO2000016764A3 (en) 2000-11-23
JP2002526184A (en) 2002-08-20
IL142129A (en) 2008-07-08
WO2000016764A2 (en) 2000-03-30
BR9914499A (en) 2001-06-26
CA2345111A1 (en) 2000-03-30
JP2002526427A (en) 2002-08-20
BR9913912A (en) 2001-06-19
AU6264399A (en) 2000-04-10
CA2345232A1 (en) 2000-03-30
AU1094300A (en) 2000-04-10
IL142130A0 (en) 2002-03-10
CA2345233A1 (en) 2000-03-30

Similar Documents

Publication Publication Date Title
US7108861B1 (en) Environmentally benign crop protection agents
Alcoverro et al. Production of mucilage by the Adriatic epipelic diatom Cylindrotheca closterium (Bacillariophyceae) under nutrient limitation
CN104995261A (en) Hydrophobic and oleophobic surfaces and uses thereof
JPH08507505A (en) Dihalotriazolopyrimidine derivatives as fungicides
RU2503179C2 (en) Synergistic combination of glyphosate and zinc pyrithione
US20040038825A1 (en) Water soluble uv-protective coatings for biological pesticides and process for making same
US20010051274A1 (en) Antifouling compounds and uses thereof
WO2002013608A1 (en) Water soluble uv-protective coatings for biological pesticides and process for making same
FI76669C (en) Process for inhibiting the growth of microbes and antimicrobial compositions containing iodonium compounds
CN104073045A (en) Application of halogenated indole and derivatives thereof as marine antifouling agent
US4066760A (en) Agricultural and horticultural fungicidal compositions
US4770705A (en) Salts of alkyl-2-benzimidazole-carbamate and fungicidal compositions thereof suitable for paints and plaster
CN114644596B (en) Fluoropyrimidine aromatic amine compound and application thereof
EP3405529B1 (en) Coating composition with antimicrobial and antisaline activity, and process for the preparation thereof
US9237750B2 (en) Ornidazole and related compounds for use as herbicides
JP2004269390A (en) Anti-microbial and deodorizing agent
CN114380802B (en) Carbazolyl-containing imidazole salt compound, and preparation method and application thereof
RU2766333C1 (en) New n4-modified 5-methyl-2'-deoxycytidines exhibiting antimicotic activity
CN111303068A (en) Structure and biological activity of benzisothiazolinone-heterocyclic antifouling paint
US4269988A (en) Biocidal mercaptotriazole haloacrylylnitrile compounds
Campbell et al. Persistence of DDT in oil-bound water-paint
US5703114A (en) Use of 4,5-dicyano-1-3-dithiole-2-one (or thione) as antimicrobial and marine antifouling agents
WO2004002224A1 (en) Composition for inhibiting gnawing and feeding by insects and animals intended to be applied on seedlings and trees
CS275634B6 (en) Agent with regulating effect to the growth of algae and chlorophyll synthesis
KR19980018190A (en) Herbicide composition and weed control method containing phenoxycarboxylic acid derivatives and microorganisms of the genus Epicoccus

Legal Events

Date Code Title Description
AS Assignment

Owner name: CUTLER, ELIOT, MAINE

Free format text: SECURITY AGREEMENT;ASSIGNOR:CERNO BIOSCIENCES, LLC;REEL/FRAME:022425/0886

Effective date: 20030315

Owner name: AMORY, DANIEL, MAINE

Free format text: SECURITY AGREEMENT;ASSIGNOR:CERNO BIOSCIENCES, LLC;REEL/FRAME:022425/0886

Effective date: 20030315

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION